MUL 1867

Drug Profile

MUL 1867

Alternative Names: MUL-1867-CF

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TGV-Laboratories
  • Developer TGV Therapeutics; TGV-Laboratories
  • Class Antibacterials; Antibronchitics; Hydrazines
  • Mechanism of Action Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Gingivitis; Periodontitis
  • Clinical Phase Unknown Pneumonia
  • Preclinical Burn infections; Conjunctivitis; Diabetic foot ulcer; Emphysema; Lung disorders; Skin and soft tissue infections; Vaginitis
  • Research Cystic fibrosis; Nosocomial pneumonia
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for clinical-Phase-Unknown development in Chronic-obstructive-pulmonary-disease in Russia (Inhalation, Aerosol)
  • 28 Dec 2017 No recent reports of development identified for clinical-Phase-Unknown development in Cystic-fibrosis in Russia (Inhalation, Aerosol)
  • 12 Apr 2016 MUL 1867 receives Orphan Drug status for Cystic fibrosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top